Merck, Bayer Drug Vericiguat Meets Primary Endpoint in Phase 3 Study
18 November 2019 - 11:14PM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Monday said vericiguat, an
investigational drug it is developing with Bayer AG (BAYN.XE), met
the primary efficacy endpoint in a phase 3 study in patients with
worsening chronic heart failure.
The Kenilworth, N.J., drug maker said vericiguat reduced the
risk of the composite endpoint of heart failure hospitalization or
cardiovascular death in patients with worsening chronic heart
failure with reduced ejection fraction compared to placebo when
given in combination with available heart failure therapies.
Merck and Germany's Bayer formed a worldwide collaboration in
October 2014 in the field of soluble guanylate cyclase modulators
such as vericiguat.
Merck said the companies will present the study results at an
upcoming medical meeting in 2020.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 18, 2019 06:59 ET (11:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bayer (TG:BAYN)
Historical Stock Chart
From Sep 2023 to Sep 2024